SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-116974"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-116974" > Effects of albendaz...

Effects of albendazole on the clinical outcome and immunological responses in helminth co-infected tuberculosis patients: a double blind randomised clinical trial

Abate, E. (författare)
Linköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Hälsouniversitetet,University of Gondar, Ethiopia
Elias, D. (författare)
University of Southern Denmark, Denmark
Getachew, A. (författare)
University of Gondar, Ethiopia
visa fler...
Alemu, S. (författare)
University of Gondar, Ethiopia
Diro, E. (författare)
University of Gondar, Ethiopia
Britton, S. (författare)
Karolinska Hospital, Sweden
Aseffa, A. (författare)
Armauer Hansen Research Institute, Ethiopia
Stendahl, Olle (författare)
Linköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Hälsouniversitetet
Schön, Thomas (författare)
Linköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Hälsouniversitetet,Kalmar County Hospital, Sweden
visa färre...
 (creator_code:org_t)
Elsevier, 2015
2015
Engelska.
Ingår i: International Journal of Parasitology. - : Elsevier. - 0020-7519 .- 1879-0135. ; 45:2-3, s. 133-140
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Despite several review papers and experimental studies concerning the impact of chronic helminth infection on tuberculosis in recent years, there is a scarcity of data from clinical field studies in highly endemic areas for these diseases. We believe this is the first randomised clinical trial investigating the impact of albendazole treatment on the clinical and immunological outcomes of helminth co-infected tuberculosis patients. A randomised, double-blind, placebo-controlled trial of albendazole (400 mg per day for 3 days) in helminth-positive tuberculosis patients was conducted in Gondar, Ethiopia. The primary outcome was clinical improvement (Delta TB score) after 2 months. Among secondary outcomes were changes in the levels of eosinophils, CD4+ T cells, regulatory T cells, IFN-gamma, IL-5 and IL-10 after 3 months. A total of 140 helminth co-infected tuberculosis patients were included with an HIV co-infection rate of 22.8%. There was no significant effect on the primary outcome (Delta TB score: 5.6 +/- 2.9 for albendazole versus 5.9 +/- 2.5 for placebo, P = 0.59). The albendazole-treated group showed a decline in eosinophil cells (P = 0.001) and IL-10 (P = 0.017) after 3 months. In an exploratory analysis after 12 weeks, the albendazole treated group showed a trend towards weight gain compared with the placebo group (11.2 +/- 8.5 kg versus 8.2 +/- 8.7 kg, P = 0.08)). The reductions in eosinophil counts and IL-10 show that asymptomatic helminth infection significantly affects host immunity during tuberculosis and can be effectively reversed by albendazole treatment. The clinical effects of helminth infection on chronic infectious diseases such as tuberculosis merit further characterisation. (C) 2014 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Helminth; Tuberculosis; Albendazole; Deworming; HIV; Ethiopia

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy